Related references
Note: Only part of the references are listed.Randomized Clinical Trial on the Effect of Bardoxolone Methyl on GFR in Diabetic Kidney Disease Patients (TSUBAKI Study)
Masaomi Nangaku et al.
KIDNEY INTERNATIONAL REPORTS (2020)
Bardoxolone methyl analog attenuates proteinuria-induced tubular damage by modulating mitochondrial function
Hajime Nagasu et al.
FASEB JOURNAL (2019)
Bardoxolone Methyl Improves Kidney Function in Patients with Chronic Kidney Disease Stage 4 and Type 2 Diabetes: Post-Hoc Analyses from Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes Study
Melanie P. Chin et al.
AMERICAN JOURNAL OF NEPHROLOGY (2018)
Guidelines for clinical evaluation of chronic kidney disease: AMED research on regulatory science of pharmaceuticals and medical devices
Eiichiro Kanda et al.
CLINICAL AND EXPERIMENTAL NEPHROLOGY (2018)
THE KEAP1-NRF2 SYSTEM: A THIOL-BASED SENSOR-EFFECTOR APPARATUS FOR MAINTAINING REDOX HOMEOSTASIS
Masayuki Yamamoto et al.
PHYSIOLOGICAL REVIEWS (2018)
Nrf2 activator for the treatment of kidney diseases
Kengo Yamawaki et al.
TOXICOLOGY AND APPLIED PHARMACOLOGY (2018)
Cardiovascular events and death in Japanese patients with chronic kidney disease
Kenichi Tanaka et al.
KIDNEY INTERNATIONAL (2017)
Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease
Vicente E. Torres et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Targeting the KEAP1-NRF2 System to Prevent Kidney Disease Progression
Masahiro Nezu et al.
AMERICAN JOURNAL OF NEPHROLOGY (2017)
Randomized Placebo-Controlled EPPIC Trials of AST-120 in CKD
Gerald Schulman et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2015)
Mechanisms Contributing to Adverse Cardiovascular Events in Patients with Type 2 Diabetes Mellitus and Stage 4 Chronic Kidney Disease Treated with Bardoxolone Methyl
Melanie P. Chin et al.
AMERICAN JOURNAL OF NEPHROLOGY (2014)
Derivative of Bardoxolone Methyl, dh404, in an Inverse Dose-Dependent Manner Lessens Diabetes-Associated Atherosclerosis and Improves Diabetic Kidney Disease
Sih Min Tan et al.
DIABETES (2014)
Risk Factors for Heart Failure in Patients With Type 2 Diabetes Mellitus and Stage 4 Chronic Kidney Disease Treated With Bardoxolone Methyl
Melanie P. Chin et al.
JOURNAL OF CARDIAC FAILURE (2014)
Integrative Biology Identifies Shared Transcriptional Networks in CKD
Sebastian Martini et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2014)
The synthetic triterpenoid RTA dh404 (CDDO-dhTFEA) restores Nrf2 activity and attenuates oxidative stress, inflammation, and fibrosis in rats with chronic kidney disease
Mohammad A. Aminzadeh et al.
XENOBIOTICA (2014)
The synthetic triterpenoid, RTA 405, increases the glomerular filtration rate and reduces angiotensin II-induced contraction of glomerular mesangial cells
Yanfeng Ding et al.
KIDNEY INTERNATIONAL (2013)
Bardoxolone Methyl in Type 2 Diabetes and Stage 4 Chronic Kidney Disease
Dick de Zeeuw et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Antioxidant treatment and outcome of cortinarius orellanus poisoning: a case series
Scott-Oliver Grebe et al.
RENAL FAILURE (2013)
The synthetic triterpenoid RTA dh404 (CDDO-dhTFEA) restores endothelial function impaired by reduced Nrf2 activity in chronic kidney disease
Mohammad A. Aminzadeh et al.
REDOX BIOLOGY (2013)
Bardoxolone methyl analogs RTA 405 and dh404 are well tolerated and exhibit efficacy in rodent models of Type 2 diabetes and obesity
Melanie Chin et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2013)
A Phase I First-in-Human Trial of Bardoxolone Methyl in Patients with Advanced Solid Tumors and Lymphomas
David S. Hong et al.
CLINICAL CANCER RESEARCH (2012)
Synthetic Oleanane Triterpenoids: Multifunctional Drugs with a Broad Range of Applications for Prevention and Treatment of Chronic Disease
Karen T. Liby et al.
PHARMACOLOGICAL REVIEWS (2012)
An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function
Frank A. Holtkamp et al.
KIDNEY INTERNATIONAL (2011)
Bardoxolone Methyl and Kidney Function in CKD with Type 2 Diabetes
Pablo E. Pergola et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Contribution of impaired Nrf2-Keap1 pathway to oxidative stress and inflammation in chronic renal failure
Hyun Ju Kim et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2010)
Effect of a Carbonaceous Oral Adsorbent on the Progression of CKD: A Multicenter, Randomized, Controlled Trial
Tadao Akizawa et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2009)
Active NF-E2-related Factor (Nrf2) Contributes to Keep Endothelial NO Synthase (eNOS) in the Coupled State ROLE OF REACTIVE OXYGEN SPECIES (ROS), eNOS, AND HEME OXYGENASE (HO-1) LEVELS
Elke H. Heiss et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
Effects of high-dose vitamin E supplementation on oxidative stress and microalbuminuria in young adult patients with childhood onset type 1 diabetes mellitus
C. Giannini et al.
DIABETES-METABOLISM RESEARCH AND REVIEWS (2007)
Direct comparison of the effects of valsartan and amlodipine on renal hemodynamics in human essential hypertension
C Delles et al.
AMERICAN JOURNAL OF HYPERTENSION (2003)
Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis - A randomized controlled trial
LY Agodoa et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2001)